Company profile
Adoram Therapeutics SA
Adoram Therapeutics is a spin-off from the University of Geneva, discovering next generation small molecule therapies for cancer and inflammation based around GPCR drug targets, the largest class of receptors in the human genome. Adoram specializes in small molecule drugs that have a sought after 'allosteric' mode of action, making them safer and more effective than conventional small molecules. Company founders include Dr. David Pejoski (Co-CEO / COO), Dr. Hesham Hamed (Co-CEO / CSO), and drug discovery advisor Prof. Leonardo Scapozza.
Source: startup.ch
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
